Dublin, April 01, 2026 (GLOBE NEWSWIRE) — The “Avastin (Bevacizumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts” has been added to ResearchAndMarkets.com’s offering.
The report offers comprehensive insights into market size, regional shares, industry segments, trends, and opportunities, essential for thriving in this sector.
The Avastin (bevacizumab) market is experiencing substantial growth, projected to expand from $7.82 million in 2025 to $8.43 million in 2026 at a CAGR of 7.8%. This growth results from several factors, including successful clinical validation, increasing global cancer rates, and widespread adoption in colorectal cancer. Future forecasts predict the market size will reach $11.27 million by 2030, with a CAGR of 7.5%, driven by the growth of bevacizumab biosimilars, a larger oncology patient pool, and increased use in emerging markets.
Key trends include sustained use of anti-angiogenic therapies, expansion into multiple cancer types, and the proliferation of biosimilars. The rise in cancer prevalence, along with an aging population and improved diagnostic methods, continues to fuel Avastin market expansion. For instance, Macmillan Cancer Support projected a rise in the number of cancer patients in the UK from 3 million in 2024 to 5.3 million by 2040, underscoring ongoing market growth.
Increased healthcare expenditures further bolster Avastin market growth. With total healthcare spending increasing by 5.6% from 2022 to 2023 in the UK, higher expenditures aid in improving insurance coverage and patient access, promoting Avastin use. As biosimilars become more prevalent, major companies emphasize their development to support competitive positioning. For instance, Bio-Thera Solutions gained FDA and EMA approvals for Avzivi, a bevacizumab biosimilar, enhancing affordability and patient access.
Roche Holding AG dominates the Avastin market, with North America being the largest regional market in 2025. Regions covered include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, with countries like Australia, India, China, South Korea, Japan, UK, France, Germany, USA, and Canada being key players.
Reasons to Purchase:
- Access the most extensive report on this market, covering 16 geographies, for a global perspective.
- Evaluate key macro factors, including geopolitical conflicts, trade policies, and regulatory changes, affecting the market.
- Develop targeted regional and country strategies based on comprehensive local data.
- Pinpoint investment-worthy growth segments.
- Gain a competitive edge using forecast data, market drivers, and trends.
- Enhance customer understanding via end-user analysis.
- Benchmark against competitors by market share, innovation, and brand strength.
- Assess the total addressable market (TAM) and market attractiveness for growth potential.
- Support your presentations with reliable, high-quality data and analysis.
- Receive updates and an Excel dashboard for data extraction and analysis.
Report Scope:
- Markets Covered by Dosage: 100 Mg; 400 Mg
- Application: Various Cancer Types, Diabetic Retinopathy, and Other Uses
- Distribution Channel: Direct Tender, Pharmacies, Online and More
- End User: Hospitals, Cancer Centers, Home Healthcare, Research Institutes
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time Series: Five years historic and ten years forecast.
Data: Market size, growth ratios, GDP relations, expenditure per capita.
Data Segmentation: Historic and forecast data by country and region, competitor market share, segments.
Delivery Format: Word, PDF, or Interactive Report with Excel Dashboard.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $8.43 Million |
| Forecasted Market Value (USD) by 2030 | $11.27 Million |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
The companies featured in this Avastin (Bevacizumab) market report include:
For more information about this report visit https://www.researchandmarkets.com/r/ifdqrz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Avastin (Bevacizumab) Market
